MediciNova (MNOV)

• Market cap: $65M
• 1 day: -1.49%
• 5 days: 4.76%
• 1 month: -5.04%
• 3 months: -6.38%
• 6 months: -8.97%
• Year to date: -0.75%
• 1 year: 3.94%
• 5 years: -64.89%
• 10 years: -80.39%
• Sector: Healthcare
• Industry: Biotechnology

About: MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Employees: 6